Systemic lanthanum is excreted in the bile of rats
- 15 June 2007
- journal article
- Published by Elsevier BV in Toxicology Letters
- Vol. 171 (1-2), 69-77
- https://doi.org/10.1016/j.toxlet.2007.04.005
Abstract
Lanthanum carbonate is a non-calcium-based oral phosphate binder for the control of hyperphosphataemia in patients with chronic kidney disease Stage 5. As part of its pre-clinical safety evaluation, studies were conducted in rats to determine the extent of absorption and routes of excretion. Following oral gavage of a single 1500 mg/kg dose, the peak plasma lanthanum concentration was 1.04 ± 0.31 ng/mL, 8 h post-dose. Lanthanum was almost completely bound to plasma proteins (>99.7%). Within 24 h of administration of a single oral dose, 97.8 ± 2.84% of the lanthanum was recovered in the faeces of rats. Comparing plasma exposure after oral and intravenous administration of lanthanum yielded an absolute oral bioavailability of 0.0007%. Following intravenous administration of lanthanum chloride (0.3 mg/kg), 74.1 ± 5.82% of the dose (96.9 ± 0.50% of recovered lanthanum) was excreted in faeces in 42 days, and in bile-duct cannulated rats, 10.0 ± 2.46% of the dose (85.6 ± 2.97% of recovered lanthanum) was excreted in bile in 5 days. Renal excretion was negligible, with <2% of the intravenous dose recovered in urine. These studies demonstrate that lanthanum undergoes extremely low intestinal absorption and that absorbed drug is predominantly excreted in the bile.Keywords
This publication has 27 references indexed in Scilit:
- Relative in Vitro Efficacy of the Phosphate Binders Lanthanum Carbonate and Sevelamer HydrochlorideJournal of Pharmaceutical Sciences, 2007
- Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic ratsNephrology Dialysis Transplantation, 2006
- Lanthanum carbonate (Fosrenol®): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patientsInternational Journal of Clinical Practice, 2005
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patientsKidney International, 2002
- Is There A Threshold of Hepatic Iron Concentration That Leads To Cirrhosis in C282y Hemochromatosis?American Journal Of Gastroenterology, 2001
- Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in managementAmerican Journal of Kidney Diseases, 2000
- Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national studyAmerican Journal of Kidney Diseases, 1998
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Metabolism of the Lanthanons in the Rat.Experimental Biology and Medicine, 1956